278 related articles for article (PubMed ID: 34879221)
1. Interleukin-10 receptor signaling promotes the maintenance of a PD-1
Hanna BS; Llaó-Cid L; Iskar M; Roessner PM; Klett LC; Wong JKL; Paul Y; Ioannou N; Öztürk S; Mack N; Kalter V; Colomer D; Campo E; Bloehdorn J; Stilgenbauer S; Dietrich S; Schmidt M; Gabriel R; Rippe K; Feuerer M; Ramsay AG; Lichter P; Zapatka M; Seiffert M
Immunity; 2021 Dec; 54(12):2825-2841.e10. PubMed ID: 34879221
[TBL] [Abstract][Full Text] [Related]
2. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.
Im SJ; Hashimoto M; Gerner MY; Lee J; Kissick HT; Burger MC; Shan Q; Hale JS; Lee J; Nasti TH; Sharpe AH; Freeman GJ; Germain RN; Nakaya HI; Xue HH; Ahmed R
Nature; 2016 Sep; 537(7620):417-421. PubMed ID: 27501248
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade.
Jadhav RR; Im SJ; Hu B; Hashimoto M; Li P; Lin JX; Leonard WJ; Greenleaf WJ; Ahmed R; Goronzy JJ
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):14113-14118. PubMed ID: 31227606
[TBL] [Abstract][Full Text] [Related]
5. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
[No Abstract] [Full Text] [Related]
6. Transcription Factor IRF4 Promotes CD8
Man K; Gabriel SS; Liao Y; Gloury R; Preston S; Henstridge DC; Pellegrini M; Zehn D; Berberich-Siebelt F; Febbraio MA; Shi W; Kallies A
Immunity; 2017 Dec; 47(6):1129-1141.e5. PubMed ID: 29246443
[TBL] [Abstract][Full Text] [Related]
7. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
[TBL] [Abstract][Full Text] [Related]
8. Frequency and functional characterization of exhausted CD8
Taghiloo S; Allahmoradi E; Tehrani M; Hossein-Nataj H; Shekarriz R; Janbabaei G; Abediankenari S; Asgarian-Omran H
Eur J Haematol; 2017 Jun; 98(6):622-631. PubMed ID: 28306177
[TBL] [Abstract][Full Text] [Related]
9. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
[TBL] [Abstract][Full Text] [Related]
10. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
11. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
[TBL] [Abstract][Full Text] [Related]
12. Dahuang Fuzi Baijiang decoction restricts progenitor to terminally exhausted T cell differentiation in colorectal cancer.
Xu Y; Wang H; Wang T; Chen C; Sun R; Yao W; Ma Y; Zhang Q; Wu L; Zeng S; Sun X
Cancer Sci; 2022 May; 113(5):1739-1751. PubMed ID: 35238098
[TBL] [Abstract][Full Text] [Related]
13. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
15. Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1
Hudson WH; Gensheimer J; Hashimoto M; Wieland A; Valanparambil RM; Li P; Lin JX; Konieczny BT; Im SJ; Freeman GJ; Leonard WJ; Kissick HT; Ahmed R
Immunity; 2019 Dec; 51(6):1043-1058.e4. PubMed ID: 31810882
[TBL] [Abstract][Full Text] [Related]
16. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision.
Chen Z; Ji Z; Ngiow SF; Manne S; Cai Z; Huang AC; Johnson J; Staupe RP; Bengsch B; Xu C; Yu S; Kurachi M; Herati RS; Vella LA; Baxter AE; Wu JE; Khan O; Beltra JC; Giles JR; Stelekati E; McLane LM; Lau CW; Yang X; Berger SL; Vahedi G; Ji H; Wherry EJ
Immunity; 2019 Nov; 51(5):840-855.e5. PubMed ID: 31606264
[TBL] [Abstract][Full Text] [Related]
17. Type 17 immunity promotes the exhaustion of CD8
Kim BS; Kuen DS; Koh CH; Kim HD; Chang SH; Kim S; Jeon YK; Park YJ; Choi G; Kim J; Kang KW; Kim HY; Kang SJ; Hwang S; Shin EC; Kang CY; Dong C; Chung Y
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083422
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
[TBL] [Abstract][Full Text] [Related]
19. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
